Accueil
Envoyer à un ami
Imprimer
Grand
Petit
Partager
ACTUALITES

CHMP adopts a positive opinion acknowledging that Jardiance® reduces the risk of CV death


- 16 Décembre 2016 modifié le 1 Janvier 1970


  • In the EMPA-REG OUTCOME® trial Jardiance® reduced the risk of cardiovascular (CV) death by 38 percent vs placebo in patients with type 2 diabetes (T2D) and established CV disease when added to standard of care
  • The Committee for Medicinal Products for Human Use (CHMP) recommends to update the existing label of Jardiance® (empagliflozin) for the treatment of adults with insufficiently controlled T2D
  • This is the first time the CHMP supports the use of a diabetes treatment for its effect on both glycaemic control and CV events